FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

NCT03042780 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Gastro-enteropancreatic Neuroendocrine Tumor
Pancreatic Cancer
Neuroendocrine Carcinomas of Pancreas
Islet Cell Carcinoma

Interventions

DRUG: FOLFIRINOX
DRUG: Granulocyte colony-stimulating factor (G-CSF)

Sponsor

H. Lee Moffitt Cancer Center and Research Institute